December 18, 2008
Chrono Therapeutics adds George Moonsammy, Ph.D. as its Senior Vice President of Clinical and Regulatory Affairs
June 23, 2008
Chrono Therapeutics adds Bret Berner, Ph.D. as its Chief Science Officer.
April 12, 2008
Chrono Therapeutics adds Dr. Lawrence Blob, MD as its Chief Medical Officer.
March 22, 2008
Chrono Therapeutics receives favorable preliminary information from the Food and Drug Administration (FDA).
March 11, 2008
Favorable Scientific Review from industry leaders of Chrono Therapeutics Human Clinical Trial Report issued from University of Basel Hospital.
February 10, 2008
Dr. Howard Maibach joins Chrono Therapeutics to lead the Advisory Board.
Company
Chrono Therapeutics Inc. (CTI)
Chrono-Pharmacological Drug Products for Next-Generation Therapies
Company
Chrono Therapeutics Inc. is a specialty pharmaceutical and product pipeline company focused on the development, commercialization and manufacture of Chrono-Pharmacological drug-products utilizing our proprietary transdermal drug delivery platform-ChronoDose™. CTI is committed to making available “smart”, next-generation market-leading drug products to help patients live fuller, healthier lives.
History
CTI, A Delaware Company, was founded by Guy DiPierro and began operations in 2004. CTI partnered with the University of Basel, Switzerland, and two other Swiss Universities and secured exclusive rights to intellectual property broadly protecting its field that was created by the University of Basel, including know-how, trade-secrets. CTI engaged the Universities initially in rapid prototyping and pharmacokinetics, and supports an aggressive, ongoing R&D program with the Swiss Universities on CTI’s behalf. CTI then moved to expand this core intellectual property portfolio through its own aggressive R&D and partnerships with its leading outsourced strategic partners.
CTI’s outsources much of its activities to our world leading partners. Its principal executive offices and device development is located in southern NJ with a portion of its pharmacokinetic and formulation R&D conducted at the University of Basel in Switzerland and at a private, cutting edge laboratory facility in San Francisco managed by transdermal formulation experts.
Future Goals
CTI’s patented Chrono-Pharmacology focused device will help ease patient suffering, ensure compliance with proper dosing regimens and decrease potential for substance abuse. We are changing the way doctors approach certain therapies, and are bringing to market patient-tailored optimized drug products.
We seek to keep families together longer, help children fulfill their potential, improve the quality of life for the elderly, and move patients towards healthier, fuller and happier lives.